MedPath

Long Term Tapering or Standard Steroids for Nephrotic Syndrome

Phase 4
Conditions
Nephrotic Syndrome
Registration Number
NCT00308321
Lead Sponsor
Institute of Child Health
Brief Summary

Parallel group double blind randomised in patients with first episode corticosteroid sensitive nephrotic syndrome comparing time to relapse and adverse effects associated with a longer tapering steroid regimen with standard regime

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • newly presenting nephrotic syndrome, urine albumin/protein creatinine ratio >200mg/mmol on early morning urine sample, hypoalbuminemia (<25g/L)
Exclusion Criteria
  • prior treatment with steroids or cytotoxic agents underlying systemic disorder or exposure to agents known to be associated with newly presenting steroid sensitive nephrotic syndrome

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Time to first relapse5 months
Assessment of steroid induced morbidity5 months
Secondary Outcome Measures
NameTimeMethod
frequent relapsing and steroid dependant disease5 months
Time to relapse5 months
serious adverse events5 months
use of other immunosuppressive agents5 months
Achenbach child behaviour checklist5 months

Trial Locations

Locations (1)

Institute of Child Health

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath